Agarwal's ASCO GU 2024 Must-Sees for Prostate Cancer January 22, 2024 By Neeraj Agarwal, MD Commentary Video Conference|Genitourinary Cancers Symposium Neeraj Agarwal, MD, highlights several exciting prostate cancer developments being presented at the upcoming 2024 Genitourinary Cancers Symposium. ...
Expert commentary previewing key studies at the 2024 ASCO Genitourinary Cancers Symposium, from Clinical Care Options (CCO)
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb(NYSE: BMY) today announced the presentation of data at the American Society of Clinical Oncology 2024 Genitourinary Cancers Symposium (ASCO GU) to be held from January 25-27 i...
Shanghai,June.3nd, 2024, Haihe Biopharma Co., Ltd. (hereby referred to as “Haihe Biopharma” or the “Company”) today announced that the clinical data of the paclitaxel oral solution and the PI3Kα inhibitor Risovalisib Mesylate were both presented in the poster section of 2024 American So...
Data presented at 2025 ASCO GU reinforce the use of agents like nivolumab, cabozantinib, and darolutamide across different genitourinary malignancies. In the adjuvant treatment of patients with muscle-invasive bladder cancer (MIBC), nivolumab (Opdivo) continued...
8. Dahan R, Sega E, Engelhardt J, et al. FcγRs modulate the anti-tumor activity of antibodies targeting the PD-1/PD-L1 axis.Cancer Cell. 2015;28(3):285-295. Related News Press Releases Merck confirms discussions with SpringWorks Therapeutics, Inc. on potential ... ...
2025年ASCO泌尿生殖系统肿瘤研讨会(ASCO-GU2025)将于2025年2月13-15日在美国加利福尼亚州旧金山举行。ASCO泌尿生殖系统肿瘤研讨会是一个为期三天的科学和教育会议,旨在满足医生和其他诊断、治疗和研究GU恶性肿瘤相关专业人士的需要。泌尿生殖道肿瘤研讨会由美国临床肿瘤学会(ASCO)、美国放射肿瘤学会(ASTRO)和美国泌尿肿...
Gilead Sciences to Release Fourth Quarter & Full Year 2024 Financial Results on Tuesday, February 11, 2025 January 28, 2025 Gilead and LEO Pharma Enter Into Strategic Partnership to Accelerate Development of Oral STAT6 Program With Potential in Multiple I...
2024 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium (#GI24), which is taking place from January 18-20. Eisai will also present research results in renal cell carcinoma (RCC) during the 2024 ASCO Genitourinary Cancers Symposium (#GU2...
Petros Grivas, MD, PhD, transitions the panel discussion to focus on clinical trial data on combination immunotherapy versus platinum chemotherapy regimens that were recently presented at ASCO GU 2022. EP: 1.Recent Treatment Advances in Urothelial Cancer EP: 2.Patient Profile: A 73-Year-Old...